Abstract
The in vitro synergistic activity of aztreonam in combination with piperacillin, moxalactam, cefotaxime, cefoperazone, and amikacin was examined against multiply resistant isolates of the family Enterobacteriaceae and Pseudomonas aeruginosa. Aztreonam in combination with amikacin demonstrated synergy against 71% of the isolates, whereas combinations of aztreonam plus a second beta-lactam demonstrated synergy against 42% of the isolates.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 283-285 |
| Number of pages | 3 |
| Journal | Antimicrobial Agents and Chemotherapy |
| Volume | 25 |
| Issue number | 2 |
| State | Published - 1984 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
Cite this
In vitro activity of aztreonam in combination with newer β-lactams and amikacin against multiply resistant gram-negative bacilli. / Buesing, M. A.; Jorgensen, J. H.
In: Antimicrobial Agents and Chemotherapy, Vol. 25, No. 2, 1984, p. 283-285.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - In vitro activity of aztreonam in combination with newer β-lactams and amikacin against multiply resistant gram-negative bacilli
AU - Buesing, M. A.
AU - Jorgensen, J. H.
PY - 1984
Y1 - 1984
N2 - The in vitro synergistic activity of aztreonam in combination with piperacillin, moxalactam, cefotaxime, cefoperazone, and amikacin was examined against multiply resistant isolates of the family Enterobacteriaceae and Pseudomonas aeruginosa. Aztreonam in combination with amikacin demonstrated synergy against 71% of the isolates, whereas combinations of aztreonam plus a second beta-lactam demonstrated synergy against 42% of the isolates.
AB - The in vitro synergistic activity of aztreonam in combination with piperacillin, moxalactam, cefotaxime, cefoperazone, and amikacin was examined against multiply resistant isolates of the family Enterobacteriaceae and Pseudomonas aeruginosa. Aztreonam in combination with amikacin demonstrated synergy against 71% of the isolates, whereas combinations of aztreonam plus a second beta-lactam demonstrated synergy against 42% of the isolates.
UR - http://www.scopus.com/inward/record.url?scp=0021352402&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021352402&partnerID=8YFLogxK
M3 - Article
C2 - 6538773
AN - SCOPUS:0021352402
VL - 25
SP - 283
EP - 285
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
SN - 0066-4804
IS - 2
ER -